Relapsed or refractory acute myeloid leukemia (AML)
Drug research and approvals for relapsed or refractory acute myeloid leukemia (AML): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 96 studies of relapsed or refractory acute myeloid leukemia (AML) are recruiting on ClinicalTrials.gov, Health Canada has authorized 19 drug trials for it since 2013, FDA has 14 approved and 23 open orphan designations naming it, and the EU has 7 authorised medicines for it.
- Recruiting worldwide: 96
- Trials authorized in Canada: 19
- FDA orphan approvals: 14
- EU medicines: 7
- Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood CancersNCT07914556 · Phase 1 · Mabwell (Shanghai) Bioscience Co., Ltd. · starts Sep 16, 2026
- Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 ExpressionNCT07809906 · Phase 1 · Orum Therapeutics USA, Inc. · starts Sep 23, 2026
- Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNCT07783100 · Phase 2 · The First Affiliated Hospital of Xiamen University · starts Nov 11, 2026
- A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)NCT07771803 · Early Phase 1 · Roger Strair · starts Jun 30, 2025
- A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AMLNCT07751991 · Phase 1 · Charm Therapeutics · starts Sep 28, 2026
- Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaNCT07668557 · Phase 1 · iCell Gene Therapeutics · starts Jun 10, 2026
- Phase I Study of FXS0683 in the Treatment of Blood TumorsNCT07616089 · Phase 1 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · starts Jun 2, 2026
- A Clinical Trial of Olutasidenib in Patients With Acute Myeloid LeukemiaNCT07604064 · Phase 2 · Kissei Pharmaceutical Co., Ltd. · starts Jun 1, 2026
- Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesNCT07523555 · Phase 1 / Phase 2 · Beijing Biotech · starts Mar 2, 2026
| Sep 25, 2026 | A phase 1/2, dose optimization and dose expansion, multicenter, open-label study to evaluate the safety, pharmacokinetics, and efficacy of menin inhibitor…Vicrimenib (S243249, BN104) | Servier | Pending |
| May 27, 2026 | A phase 1b study of the safety and pharmacokinetics of pivekimab sunirine in pediatric subjects with relapsed or refractory acute myeloid leukemia (AML)Pivekimab sunirine (IMGN-632) | AbbVie | Pending |
| May 26, 2026 | A phase 2 trial of gilteritinib in combination with azacitidine and venetoclax to overcome venetoclax resistance in patients with relapsed/refractory FLT3-wild…Gilteritinib | BC Cancer, Part of The Provincial Health Services Authority | Pending |
| Mar 20, 2024 | Phase I multicenter, open-label, first-in-human study of BMS-986497 (ORM-6151) in subjects with relapsed or refractory acute myeloid leukemia or…BMS-986497 (ORM-6151) | Bristol-Myers Squibb | Closed |
| Mar 25, 2022 | Managed access program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification…Kymriah | Novartis Pharmaceuticals | Pending |
| Jul 8, 2021 | A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine versus physician's choice of…Magrolimab | Gilead Sciences | Closed |
| Jun 18, 2021 | A phase 1b dose escalation study of lemzoparlimab (TJ011133) in combination with azacitidine and/or venetoclax in subjects with acute myeloid leukemia (AML) or…Lemzoparlimab/ Venetoclax/ Azacitidine | AbbVie | Pending |
| May 6, 2020 | An open-label feasibility study to assess the safety and pharmacokinetics of enasidenib in pediatric patients with relapsed/refractory acute myeloid leukemia…Enasidenib | Childrens Oncology Group | Ongoing |
| Oct 11, 2019 | A phase 1/2, multi-center, dose-escalating study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of quizartinib administered in…Quizartinib | Daiichi Sankyo | Ongoing |
| Sep 20, 2019 | A phase I/II, multicenter, open-label, multi-arm study evaluating the safety, tolerability, pharmacokinetics, and preliminary activity of idasanutlin in…Idasanutlin (RO5503781) / Venetoclax (RO5537382) / Cytarabine / Topotecan /… | Roche | Closed |
| May 13, 2026 | InqoviIn combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have… | Taiho Oncology Inc. | Approved |
| Nov 13, 2025 | KomziftiTreatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who… | Kura Oncology, Inc. | Approved |
| Oct 24, 2025 | RevuforjTreatment of relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric… | Syndax Pharmaceuticals, Inc. | Approved |
| Dec 1, 2022 | RezlidhiaTreatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1)… | Rigel Pharmaceuticals, Inc. | Approved |
| May 25, 2022 | TibsovoIn combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible… | Servier Pharmaceuticals LLC | Approved |
| Mar 30, 2021 | VYXEOS ; Vyxeos ; VyxeosTreatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults… | Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company) | Approved |
| May 2, 2019 | TibsovoTIBSOVO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1)… | Servier Pharmaceuticals LLC | Approved |
| Nov 28, 2018 | XospataXOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like… | Astellas Pharma US, Inc. | Approved |
| Nov 21, 2018 | DaurismoDAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult… | Pfizer, Inc. | Approved |
| Nov 21, 2018 | VenclextaVENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute… | AbbVie Inc. | Approved |
| Jul 20, 2018 | TibsovoTIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible… | Servier Pharmaceuticals LLC | Approved |
| Aug 3, 2017 | VYXEOS ; Vyxeos ; VyxeosTreatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) | Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company) | Approved |
| Aug 1, 2017 | IdhifaTreatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as… | Celgene Corporation | Approved |
| Apr 28, 2017 | RydaptTreatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved… | Novartis Pharmaceuticals Corporation | Approved |
| Apr 24, 2024 | Selective small molecule messenger RNA (mRNA) degrader of…Treatment of acute myeloid leukemia (AML) | Remix Therapeutics | Designated |
| Sep 15, 2023 | InaqoviCedazuridine; decitabine | Otsuka Pharmaceutical Netherlands B.V. | EMA ↗ |
| May 4, 2023 | TibsovoIvosidenib · orphan | Les Laboratoires Servier | EMA ↗ |
| Jun 17, 2021 | OnuregAzacitidine | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Jun 26, 2020 | DaurismoGlasdegib · orphan | Pfizer Europe MA EEIG | EMA ↗ |
| Oct 24, 2019 | XospataGilteritinib · orphan | Astellas Pharma Europe B.V. | EMA ↗ |
| Aug 23, 2018 | Vyxeos liposomal (previously Vyxeos)Daunorubicin; cytarabine · orphan | Jazz Pharmaceuticals Ireland Limited | EMA ↗ |
| Sep 20, 2012 | DacogenDecitabine | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA